Article

Explore manufacturability, purification strategies, and expected yields for over 70 bispecific antibody formats to support informed decision-making in therapeutic development.

Integrated software and AI are accelerating drug discovery through faster analysis and smarter decisions.

Advances in microfluidics are enabling more powerful, high throughput applications in single cell and therapeutic discovery.

Collaboration to leverage Oxford Nanopore’s sequencing platform and Cepheid’s GeneXpert system to advance the field of sequencing for infectious diseases.

Collaboration combines Scipher’s unique RNAseq data with InnoSIGN’s proprietary comprehensive pathway analysis (CPA) platform to enhance the understanding of complex immune-mediated diseases.

Planned acquisition will strengthen the presence of the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and expand reach of SpringWorks' therapeutic innovations to more patients with rare tumors worldwide

Integrating scientific and engineering expertise is critical for enabling faster, more cost-effective drug discovery. 

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs.

Validated drug discovery assay overcomes previous challenges in targeting NaV1.9 ion channels for chronic pain signalling

EpiCypher has launched meCUT&RUN and Multiomic CUT&RUN, two cost-effective tools for high-resolution DNA methylation and multiomic epigenomic profiling.

Bruker has launched Beacon Discovery™, a benchtop system for live single-cell analysis designed for broader use in academic and translational research.

Built on the legacy of three trusted brands – BioTrading, Redipor by Cherwell, and NEL – Redipor by AnalytiChem brings together over 150 years of prepared media expertise, innovation and heritage into one unique global brand.

Promising new data shows that Factor H (CPV-104) significantly reduces inflammation and retinal degeneration in an animal model of dry age-related macular degeneration

Cyprumed GmbH and MSD have entered a non-exclusive agreement to develop oral peptide formulations using Cyprumed’s delivery technology.

ProBioGen announced the commercial launch of Ziihera®, a bispecific antibody for HER2-positive biliary tract cancer developed with its GlymaxX® technology.

A new benchtop system enables real-time live single-cell functional analysis for immune response, antibody discovery, and cell therapy.

Synthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods.